Overview: Hepatitis B Core IgM TestIntroduction: The Hepatitis B Core IgM Test detects IgM antibodies to hepatitis B core to diagnose acute hepatitis B, causing liver pain or jaundice. Aligned with 2023 AASLD guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antiviral therapy, and improving outcomes in serology for patients with suspected acute hepatitis B.
Other Names: Anti-HBc IgM Assay, Acute Hepatitis B Core Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: Hepatitis B core antibody testing began in the 1970s with HBV research. IgM immunoassays improved in the 1980s, enhancing acute infection detection.
Purpose: Diagnoses acute hepatitis B, guides antiviral therapy, and monitors anti-HBc IgM in patients with liver pain or jaundice.
Test Parameters: 1. Hepatitis B Core IgM
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like liver pain, jaundice, or fatigue, and list medications.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver pain, jaundice, fatigue, or history of hepatitis B exposure. Include current medications and risk factors (e.g., IV drug use).
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy.
Procedural Considerations: Uses an immunoassay to detect anti-HBc IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Improper sample handling or early infection can affect results. Cross-reactivity with other infections may occur.
Clinical Significance: Positive anti-HBc IgM indicates acute hepatitis B, prompting antiviral therapy or monitoring. Negative results may require repeat testing in early infection.
Specialist Consultation: Consult a hepatologist or infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: HBsAg, HBV DNA, or liver function tests to confirm acute hepatitis B.
Test Limitations: False negatives may occur in early infection. Clinical correlation is needed.
References: AASLD Hepatitis B Guidelines, 2023; Hepatology, Lok AS, 2022.
